Table 3. Validation of hepatocellular carcinoma-related mutations in the reverse transcriptase domain of hepatitis B virus polymerase.

	Validation set I				Validation set II
Mutation	HCC (n = 97)*	Non-HCC (n = 97)*	P	Crude OR (95% CI) †	HCC (n = 105)*	Non-HCC (n = 105)*	P	Crude OR (95% CI) †
A799G	15 (15.5)	5 (5.2)	0.018	3.37 (1.17–9.67)	15 (14.3)	6 (5.7)	0.038	2.75 (1.02–7.39)
T843C	16 (16.5)	26 (26.8)	0.081	0.54 (0.27–1.09)	31 (29.5)	32 (30.5)	0.880	0.96 (0.53–1.73)
T870C	7 (7.2)	5 (5.2)	0.551	1.43 (0.44–4.68)	10 (9.5)	6 (5.7)	0.298	1.74 (0.61–4.97)
T895A	48 (49.5)	43 (44.3)	0.472	1.23 (0.70–2.16)	58 (55.2)	53 (50.5)	0.489	1.21 (0.70–2.08)
T906R	4 (4.1)	2 (2.1)	0.683	2.04 (0.37–11.42)	7 (6.7)	10 (9.5)	0.448	0.68 (0.25–1.86)
C936T	21 (21.6)	29 (29.9)	0.189	0.65 (0.34–1.24)	37 (35.2)	42 (40.0)	0.476	0.82 (0.47–1.43)
A942S	7 (7.2)	10 (10.3)	0.446	0.68 (0.25–1.86)	8 (7.6)	12 (11.4)	0.347	0.64 (0.25–1.63)
A987G	11 (11.3)	2 (2.1)	0.010	6.08 (1.31–28.19)	5 (4.8)	1 (1.0)	0.210	5.20 (0.60–45.29)
T1055A	22 (22.7)	6 (6.2)	0.001	4.45 (1.72–11.54)	13 (12.4)	4 (3.8)	0.023	3.57 (1.12–11.33)
T1069A	0 (0.0)	0 (0.0)	/	/	5 (4.8)	0 (0.0)	0.070	/
T1071C	0 (0.0)	0 (0.0)	/	/	4 (3.8)	0 (0.0)	0.130	/

Abbreviations: CI, confidence interval; HCC, hepatocellular carcinoma; OR, odds ratio.

*Data are presented as n (%).

^†Crude odds ratios were calculated using a two-by-two frequency table.